Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Aug 26;14(3):678-682.
doi: 10.3390/neurolint14030056.

A Patient with Erdheim-Chester Disease Limited to Central Nervous System

Affiliations
Case Reports

A Patient with Erdheim-Chester Disease Limited to Central Nervous System

Rajesh K Gupta et al. Neurol Int. .

Abstract

Erdheim-Chester disease (ECD) is a rare, sporadic, non-Langerhans cell histiocytosis, a multisystem disorder, which has higher mortality when presented with CNS involvement. We report a 46-year-old woman who has ECD with exclusive CNS involvement. She presented with intracranial hemorrhage and had a poor response to corticosteroid and interferon. She required multiple debulking procedures and eventually responded well to cobimetinib. She has not had any other organ involvement thus far. This report highlights that CNS involvement may be the only manifestation of ECD and sometimes may require a repeat biopsy with IHC testing for excellent treatment outcomes.

Keywords: CNS; Erdheim-Chester disease (ECD); histiocytosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Patient’s Brain MRI. (AC) show brain MRI at the time of initial presentation in 2013, (A) is T2, (B) is T1 FLAIR, and (C) is T2 FLAIR. (DF) is brain MRI 3 months after the patient’s initial craniotomy. (D) is T2, (E) is T1 FLAIR, and (F) is T2 FLAIR. (GI) is 7 years after initial MRI, (after the patient was on cobimetinib for 6 months). (G) is T2, (H) is T1 FLAIR, and (I) is T2 FLAIR. (JL) are 8 years after initial MRI, (on cobimetinib for 13 months). (J) is T2, (K) is T1 FLAIR and (L) is T2 FLAIR. Single yellow arrows in different figures shows the lesion after biopsy and debulking. In (L), anterior and first arrow is highlighting meningioma in addition to lesion as denoted by 2nd and posterior arrow.
Figure 2
Figure 2
Immunohistochemistry pictures from biopsy in 2019. (A): Hematoxylin and Eosin 200×, areas of histiocytic and monocyte infiltration. (B): Hematoxylin and Eosin 400×, areas of monocyte infiltration consistent with macrophages and monocytes. (C): CD68 Immunohistochemistry 400×, Areas of monocyte infiltration consistent with macrophages and monocytes. (D): H and E stain 400×, areas of monocyte infiltration consistent with macrophages and monocytes.

References

    1. Chester W. Über lipoidgranulomatose. Virchows Arch. Pathol. Anat. Physiol. Klin. Med. 1930;279:561–602. doi: 10.1007/BF01942684. - DOI
    1. Haroche J., Cohen-Aubart F., Amoura Z. Erdheim-Chester disease. Blood. 2020;135:1311–1318. doi: 10.1182/blood.2019002766. - DOI - PubMed
    1. Noh S.-M., Kang H.G. Embolic Infarction with Subdural Hemorrhage in Erdheim-Chester Disease. J. Clin. Neurol. 2020;16:349–351. doi: 10.3988/jcn.2020.16.2.349. - DOI - PMC - PubMed
    1. Bhatia A., Hatzoglou V., Ulaner G., Rampal R., Hyman D.M., Abdel-Wahab O., Durham B.H., Dogan A., Ozkaya N., Yabe M., et al. Neurologic and oncologic features of Erdheim–Chester disease: A 30-patient series. Neuro-Oncology. 2020;22:979–992. doi: 10.1093/neuonc/noaa008. - DOI - PMC - PubMed
    1. Lachenal F., Cotton F., Desmurs-Clavel H., Haroche J., Taillia H., Magy N., Hamidou M., Salvatierra J., Piette J.-C., Vital-Durand D., et al. Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: Report of 6 cases and systematic review of the literature. J. Neurol. 2006;253:1267–1277. doi: 10.1007/s00415-006-0160-9. - DOI - PubMed

Publication types

LinkOut - more resources